title: IBD: Adalimumab for ulcerative colitis— is the glass half empty or half full?
abstract: Antibodies that target tumor necrosis factor are effective at inducing and maintaining remission in both Crohn's disease (infliximab, adalimumab and certolizumab) and ulcerative colitis (infliximab). The results of a randomized controlled trial of adalimumab for inducing remission in moderately to severely active ulcerative colitis have now been published.
authors.affiliation: Internal Medicine and Gastroenterology Unit, Complesso Integrato Columbus, Catholic University, Via Moscati 31, Rome, Italy. alearmuzzi@yahoo.com
authors.forename: Alessandro
authors.initials: A
authors.lastname: Armuzzi
authors.forename: Daniela
authors.initials: D
authors.lastname: Pugliese